On July 8, Insilico Medicine rose 5.16% in regular trading, trading at HK$38.02/share, with turnover of HK$185 million, reversing the prior session's decline.

On the news front, the company announced that its self-developed TNIK small molecule inhibitor Rentosertib has officially entered Phase III clinical trials, with registration completed on both the CDE platform and ClinicalTrials.gov. The prospective, randomized, double-blind, placebo-controlled study plans to evaluate 52 weeks of once-daily dosing across 47 research centers in China, enrolling 320 subjects for idiopathic pulmonary fibrosis treatment.

Rentosertib is the world's first drug candidate fully discovered and designed by generative AI to complete a Phase IIa trial. It received FDA Orphan Drug Designation in February 2023 and was included in CDE's breakthrough therapy list in May 2025. Analysts noted that if successfully commercialized, it could become a disruptive therapy. The milestone comes amid a series of recent catalysts including a $600 million Takeda collaboration and a $2.5 billion SK Biopharmaceuticals partnership.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)